Business Wire

Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma

Jaa

Pierre Fabre today announced that the European Commission (EC) has granted marketing authorisation for the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.1,2 The EC decision is applicable to all 28 European Union (EU) member states plus Liechtenstein, Iceland and Norway.

"We are extremely pleased that European patients with advanced BRAF-mutant melanoma will now have the combination of BRAFTOVI and MEKTOVI as a new treatment option”, said Frédéric Duchesne, President & CEO of the Pierre Fabre Pharmaceuticals Division. “All of us at Pierre Fabre are driven to make a real difference for patients. Bringing more than 30 years of oncology experience and our heritage in dermatology to our partnership with Array BioPharma, we have been able to harness our expertise in order to help men and women living with this devastating disease. Today’s news inspires us to continue pursuing new innovations that will benefit patients”.

The EC decision, which follows the positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in July, is based on results from the Phase 3 COLUMBUS trial.3 This trial demonstrated that the combination of BRAFTOVI 450 mg once daily and MEKTOVI 45 mg twice daily significantly improved median progression-free survival (PFS), compared with vemurafenib alone 960 mg twice daily (14.9 months versus 7.3 months, respectively: hazard ratio [HR] 0.54, 95% confidence interval [CI], 0.41–0.71; two-sided p<0.0001).3 Data published in The Lancet Oncology 4 in September 2018 demonstrated that treatment with BRAFTOVI and MEKTOVI achieved a median overall survival (OS) of 33.6 months, compared with 16.9 months for patients treated with vemurafenib as a monotherapy (HR 0.61, 95% CI, 0.47–0.79; p<0.0001) in the planned analysis of OS in the COLUMBUS trial4. The most common adverse reactions (≥25%) occurring in patients treated with BRAFTOVI administered with MEKTOVI at the recommended dose (n=274 based on two Phase II trials and COLUMBUS) were fatigue, nausea, diarrhoea, vomiting, retinal detachment, abdominal pain, arthralgia, increased blood creatine kinase and myalgia.1,2 In the COLUMBUS trial, adverse events leading to discontinuation that were suspected to be related to the study treatment occurred in 6% of patients.3,4

“The European Commission’s approval is an important advance in improving the prognosis of patients with advanced BRAF-mutant melanoma”, said Professor Reinhard Dummer, University of Zürich, Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland, and investigator of the COLUMBUS study. “Physicians and patients will now have BRAFTOVI and MEKTOVI as an effective and well-tolerated treatment combination option, which has been shown to delay disease progression and potentially prolong patients’ lives”.

Important safety information and recommendations for the use of BRAFTOVI and MEKTOVI are detailed in the Summary of Product Characteristics (SmPC), published in the European public assessment report (EPAR) and available in all official EU languages.
See full SmPC at: http://www.ema.europa.eu.

On 27 June 2018, Pierre Fabre’s partner Array BioPharma, which has exclusive rights for these medicines in the United States (US), announced that the combination of BRAFTOVI and MEKTOVI was approved by the US Food and Drug Administration (FDA) for the treatment of unresectable or metastatic melanoma with a BRAF V600E or BRAF V600K mutation, as detected by an FDA-approved test.5,6 BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma.

About BRAF-mutant Metastatic Melanoma
Melanoma develops when unrepaired DNA damage to skin cells triggers mutations that may lead them to multiply and form malignant tumours. Metastatic melanoma is the most serious and life-threatening type of skin cancer and is associated with low survival rates.7,8 There are a variety of gene mutations that can lead to metastatic melanoma. The most common genetic mutation in metastatic melanoma is BRAF. There are more than 100,000 new cases of melanoma diagnosed in Europe each year,9 approximately half of which have BRAF mutations, a key target in the treatment of metastatic melanoma.10–11

About BRAFTOVI (encorafenib) and MEKTOVI (binimetinib)
BRAFTOVI (encorafenib) is an oral small-molecule BRAF kinase inhibitor and MEKTOVI (binimetinib) is an oral small-molecule MEK inhibitor that targets key enzymes in the MAPK signalling pathway (RAS-RAF-MEK-ERK). Inappropriate activation of proteins in this pathway has been shown to occur in many cancers, including melanoma, colorectal cancer, non-small-cell lung cancer, thyroid and others.

Pierre Fabre has exclusive rights to develop and commercialise BRAFTOVI and MEKTOVI worldwide, except in the US and Canada, where Array BioPharma retains exclusive rights; Israel, where Medison has exclusive rights; and in Japan and South Korea, where Ono Pharmaceutical has exclusive rights to commercialise both products.

BRAFTOVI + MEKTOVI Abbreviated EU Prescribing Information
▼These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of SmPC for how to report adverse reactions.

Name of the medicinal products: BRAFTOVI (encorafenib) 75 mg hard capsules and 50 mg hard capsules. MEKTOVI (binimetinib) 15 mg film-coated tablets.

Clinical particulars:
Therapeutic indications: Encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Posology and method of administration: Encorafenib treatment in combination with binimetinib should be initiated and supervised under the responsibility of a physician experienced in the use of anticancer medicinal products. Posology: The recommended dose of encorafenib is 450 mg (six 75 mg capsules) once daily, when used in combination with binimetinib. The recommended dose of binimetinib is 45 mg (three 15 mg tablets) twice daily corresponding to a total daily dose of 90 mg approximately 12 hours apart. Dose modification : The management of adverse reactions may require dose reduction, temporary interruption or treatment discontinuation (for complete information, please refer to SmPC 4.2 section). Method of administration: For oral use. The capsules of encorafenib are to be swallowed whole with water. They may be taken with or without food. The concomitant administration of encorafenib with grapefruit juice should be avoided. The tablets of binimitinib are to be swallowed whole with water. They may be taken with or without food.

Contraindications: Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of the BRAFTOVI and MEKTOVI SmPc.

Special warnings and precautions for use: Encorafenib and binimetinib have to be given in combination. Before taking encorafenib in combination with binimetinib, patients must have BRAFV600 mutation confirmed by a validated test. For complete information on the following special warnings and precautions for use: Patients who have progressed on a BRAF inhibitor, patients with brain metastases. Left ventricular dysfunction, Haemorrhage, ocular toxicities. QT Prolongation, New primary malignancies, Cutaneous and non-cutaneous malignancies, Liver laboratory abnormalities, Hepatic impairment, Renal impairment, CK elevation and rhabdomyolysis, Hypertension, Venous thromboembolism (VTE), Pneumonitis/Interstitial lung disease, Lactose intolerance, please refer to BRAFTOVI and MEKTOVI SmPC 4.4 section.

Interaction with other medicinal products and other forms of interaction: Encorafenib is primarily metabolised by CYP3A4. Therefore, concomitant administration of encorafenib with strong CYP3A4 inhibitors should be avoided. Agents that are CYP3A4 substrates (inhibitor and inducer) should be co-administered with caution. Binimetinib is primarily metabolised through UGT1A1 mediated glucuronidation. Therefore, inducers and inhibitors of UGT1A1 should be co-administered with caution. For complete information, please refer to SmPC, 4.5 section.

Undesirable effects: Summary of safety profile: At the recommended dose (n=274) in patients with metastatic melanoma, the most common adverse reactions (≥ 25%) occurring in patients treated with encorafenib administered with binimetinib were fatigue, nausea, diarrhea, vomiting, retinal detachment, abdominal pain, arthralgia, blood CK increased and myalgia. For complete information, please refer to BRAFTOVI and MEKTOVI SmPC 4.8 section.

For complete information please refer to the full SmPC which can be found at: http://www.ema.europa.eu.

About COLUMBUS
The COLUMBUS trial (NCT01909453) is a two-part, international, randomised, open-label, Phase 3 trial evaluating the efficacy and safety of BRAFTOVI (encorafenib) in combination with MEKTOVI (binimetinib) compared with vemurafenib and encorafenib monotherapy in 921 patients with locally advanced, unresectable or metastatic melanoma with BRAF V600 mutation.12 The primary endpoint of the trial was median progression-free survival (PFS); all secondary efficacy analyses, including the prospectively planned analysis overall survival (OS), are descriptive in nature. More than 200 sites across North America, Europe, South America, Africa, Asia and Australia participated in the COLUMBUS trial.

The EC decision is based on results from the Phase 3 COLUMBUS trial, which demonstrated that the combination improved median PFS, compared with vemurafenib alone (14.9 months versus 7.3 months, respectively: HR 0.54, 95% CI, 0.41–0.71; p<0.001).1–3 As presented at ASCO in June 2018, treatment with BRAFTOVI and MEKTOVI achieved a median OS of 33.6 months, compared with 16.9 months for patients treated with vemurafenib as a monotherapy (HR 0.61, 95% CI, 0.47–0.79; p<0.0001) in the planned analysis of OS in the COLUMBUS trial.1–2,4 Adverse events leading to discontinuation that were suspected to be related to the study treatment occurred in 6% of patients.3,4 The most common Grade 3–4 adverse events, seen in more than 5% of patients, were: increased gamma-glutamyltransferase (9%), increased creatine phosphokinase (7%) and hypertension (6%).3,4

About Pierre Fabre

To find out more Pierre Fabre, please go to www.pierre-fabre.com

References
[1] European Medicines Agency. BRAFTOVI® (encorafenib) Summary of Product Characteristics.. Available at: http://www.ema.europa.eu. Publication pending (September 2018).
[2] European Medicines Agency. MEKTOVI® (binimetinib) Summary of Product Characteristics. Available at: http://www.ema.europa.eu. Publication pending (September 2018).
[3] Dummer R, et al. Lancet Oncol 2018;19:603–615.
[4] Dummer R, et al. Lancet Oncol 2018. Available at: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30497-2/fulltext Accessed September 2018.
[5] Array BioPharma. BRAFTOVI® US Prescribing Information 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf. Accessed September 2018.
[6] Array BioPharma. MEKTOVI® US Prescribing Information 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf. Accessed September 2018.
[7] American Cancer Society. Melanoma Skin Cancer. Available at: https://www.cancer.org/cancer/melanoma-skin-cancer.html. Accessed September 2018.
[8] National Cancer Institute. Survival by Stage. Available at: https://seer.cancer.gov/statfacts/html/melan.html. Accessed September 2018.
[9] Melanoma Patient Network Europe. Melanoma – The Facts. Available at: http://www.melanomapatientnetworkeu.org/melanoma.html. Accessed September 2018.
[10] Klein O, et al. Eur J Cancer 2013;49:1073–1079.
[11] American Cancer Society. What Causes Melanoma Skin Cancer? 2016. Available at: https://www.cancer.org/cancer/melanoma-skin-cancer/causes-risks-prevention/what-causes.html. Accessed September 2018.
[12] Clinical Trials.gov. Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS). Available at: https://clinicaltrials.gov/ct2/show/NCT01909453. Accessed September 2018.

###

Contact information

Pierre Fabre
Valérie Roucoules, (33) 1 49 10 83 84
valerie.roucoules@pierre-fabre.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Takeda and the New York Academy of Sciences Announce 2019 Innovators in Science Award Winners12.12.2018 16:00Tiedote

Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502) and the New York Academy of Sciences announced today the Winners of the second annual Innovators in Science Award for their commitment to and excellence in regenerative medicine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181212005061/en/ The 2019 Winner of the Senior Scientist Award is Michele De Luca, M.D., Professor of Biochemistry and Director of the Centre for Regenerative Medicine “Stefano Ferrari”, University of Modena and Reggio Emilia in Modena, Italy. Dr. De Luca has dedicated his career in translational medicine to developing stem cell therapies and is a leading authority on human squamous epithelial stem cell biology. “Breakthroughs in regenerative medicine start with basic science and developmental biology. It’s an honor to be recognized for my research in epithelial stem cells and for my contributions in expanding their therapeutic potential,” sai

Wipro Achieves ‘Cloud Elite’ Status in Oracle PartnerNetwork Cloud Program12.12.2018 15:40Tiedote

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has achieved the ‘Cloud Elite’ status in the Oracle PartnerNetwork (OPN) Cloud Program. The Oracle Cloud Elite status is conferred upon highly skilled Oracle partners who have managed multiple cloud implementations for clients across the globe in the Software as a service (SaaS), Platform as a Service (PaaS) and Infrastructure as a service (IaaS) space. Typically, these are companies that have demonstrated strong cloud delivery capabilities, have been endorsed by their customers, and have a significant pool of resources skilled in technologies related to Oracle Cloud. Ravi Purohit, Vice President & Global Head – Oracle service line, Modern Application Services, Wipro Limited said, “We are proud of how our relationship with Oracle has grown and gone from strength to strength, over the years. The Oracle Cloud Elite status i

SailPoint Releases Industry’s First Identity Annual Report12.12.2018 15:00Tiedote

SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance, today released the 2018 Identity Report, the industry’s first benchmark. In 2017, SailPoint launched a free assessment tool to help identify areas of exposure for companies, which automatically computed an “Identity Score” based on its results. After analyzing hundreds of completed self-assessments and the correlating Identity Scores, SailPoint found that while the majority of organizations have an identity program in place, there is still much work to be done to address holes in their security programs. To download the report, please visit https://www.sailpoint.com/IdentityReport “IT leaders are struggling to secure an increasingly complex IT environment, driven by the need to govern a diverse population of users, now including non-human users like software bots, as well as an explosion of both applications and data,” said Kari Hanson, Vice President of Corporate Marketing, SailPoint. “Ou

LTI Appoints Nachiket Deshpande as Chief Operating Officer12.12.2018 14:00Tiedote

Larsen & Toubro Infotech (BSE: 540005, NSE: LTI), a global technology consulting and digital solutions company, has appointed Nachiket Deshpande as its Chief Operating Officer. Nachiket brings more than 23 years of rich experience in delivery management, customer relationships management, account and P&L management across verticals, technologies and geographies. In his last role as the Senior Vice President & Global Delivery Head for the Banking and Financial Services unit at Cognizant Technology Solutions, he was responsible for global delivery and P&L across all services lines, products, and platforms, as well as driving large-scale skills transformation. In a career spanning more than two decades, he has held management positions in the US, Europe, and Asia across delivery, practice building and client facing roles. Sanjay Jalona, Chief Executive Officer & Managing Director, LTI, said, “Nachiket joins us at an exciting phase of LTI’s transformation as customers entrust us with solvi

ABB: Statement12.12.2018 13:25Tiedote

ABB confirms that it is currently in discussions with Hitachi to expand and re-define the existing strategic power grid partnership between the two companies announced in December 2014. There can be no certainty that any transaction will occur, or as to the timing, structure or terms of any transaction. This information is information that ABB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 11:00 CET on December 12, 2018. ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader in power grids, electrification products, industrial automation and robotics and motion, serving customers in utilities, industry and transport & infrastructure globally. Continuing a history of innovation spanning more than 130 years, ABB today is writing the future of industrial digitalization with two clear value propositions: bringing electricity from any power plant to any plug a

Amazon Web Services Launches New Region in Sweden12.12.2018 11:36Tiedote

Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ:AMZN), today announced the opening of the AWS Europe (Stockholm) Region. With this launch, AWS now provides 60 Availability Zones across 20 infrastructure regions globally, with another 12 Availability Zones and four regions in Bahrain, Hong Kong SAR, Italy, and South Africa all coming online by the first half of 2020. The AWS Europe (Stockholm) Region is AWS’s fifth in Europe, joining existing regions in France, Germany, Ireland, and the UK. Tens of thousands of customers across the Nordics – Denmark, Finland, Iceland, Norway, and Sweden – already use AWS. Starting today, developers, startups, and enterprises, as well as government, education, and non-profit organizations can leverage the new AWS Europe (Stockholm) Region to run their applications in Sweden, serve end-users across the Nordics with lower latency, and leverage advanced technologies such as analytics, database, mobile services, serverless, and more, to drive

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme